|
| Author/year | Study type | No. of pts | Male, no. (%) | Female, no. (%) | Age, mean ± SD | CHA2DS2-VASc score, mean ± SD; median ± IQR | HAS-bled score, mean ± SD; median ± IQR | Type of intracranial hemorrhage | Duration between device implant and intracranial hemorrhage |
|
| Ajmal/2020 | Retrospective observation | 16 | 9 (56.2%) | 7 (43.8%) | 74.6 ± 5.8 | Median 4.5; IQR 3 | Median 4; IQR 1 | 7 IPH
7 SDH
2 SAH | More than 2 months |
| Fayos-Vidal/2020 | Retrospective observation | 9 | 7 (77.7%) | 2 (22.3%) | 72.7 ± 8.2 | Median 4; IQR 2.5 | Median 3; IQR 0 | 8 IPH
1 SDH | Less than 1 months in 5
More than 1 months in 4 |
| Pouru/2020 | Prospective registry | 104 | 73 (70.1%) | 31 (29.9%) | 73 ± 7 | Mean ± SD: 4.7 ± 1.4 | Mean ± SD: 3.3 ± 0.9 | 69 IPH
21 SDH
11 SAH
2 not reported | Median: 7 Months |
| Hucker/2019 | Retrospective observation | 63 | 37 (58.7%) | 26 (41.3%) | 75.3 ± 6.0 | Mean ± SD: 4.9 ± 1.7 | Mean ± SD: 3.5 ± 1.1 | 36 IPH
18 SDH
6 SAH
3 uncertain | Median: 212 days; IQR: 78–548 days |
| Hutt/2019 | Prospective registry | 38 | 19 (50%) | 19 (50%) | 73 ± 7 | Mean ± SD: 5.0 ± 1.3 | Mean ± SD: 4.2 ± 1.0 | 23 IPH
9 SDH
6 SAH | Median 637 days, minimum 60 days |
| Nielsen-Kudsk/2017 | Retrospective observation | 151 | 99 (65.6%) | 52 (34.4%) | 71.9 ± 8.7 | Mean ± SD: 3.9 ± 1.5 | Mean ± SD: 4.2 ± 0.8 | Not reported | Median: 203 days; IQR: 99–982 |
| Tzikas/2017 | Prospective registry | 198 | 138 (70%) | 60 (30%) | 73.7 ± 7.9 | Mean ± SD: 4.5 ± 1.5 | Mean ± SD: 3.5 ± 1.1 | Not reported | Not reported |
| Renou/2017 | Prospective observation | 46 | 29 (63%) | 17 (37%) | 73.7 ± 8.4 | Mean ± SD: 5.23 ± 1.12 | Mean ± SD: 4.00 ± .95 | 43 IPH
3 others | Mean ± SD: 7 ± 4 mo |
| Martínez-Domeño/2017 | Retrospective observation | 9 | 7 (77.7%) | 2 (22.3) | 72.7 ± 8.2 | Median 4 | Median 3 | Not reported | 4 with 1 month rest not reported |
| Cru-Gonzal/2017 | Retrospective observation | 47 | 25 (53.1%) | 22 (46.9%) | 80 ± 6 | Mean ± SD: 5 ± 1 | Mean ± SD: 4±1 | 34 IPH
10 SDH
2 SAH
1 microhemorrhages | Less than 3 months 11
More than 3 months 36 |
| Fahmy/2016 | Retrospective observation | 26 | 16 (61.5%) | 10 (38.5%) | 76 ± 7.0 | Mean ± SD: 4.9 ± 1.7 | Mean ± SD: 4.4 ± 0.6 | 24 IPH
2 ocular hemorrhage | Mean ± SD: 30 ± 48 mo |
| Horstman/2014 | Prospective observation | 20 | 14 (70%) | 6 (30%) | 72.6 ± 5.8 | Mean: 4.5 ± 1.4 | Mean ± SD: 4.7 ± 1.0 | 15 IPH
4 SDH
1 SAH | Mean ± SD: 23.1 ± 28.6 mo |
|
